(VIANEWS) – Two Harbors Investment Corp (TWO), Halozyme Therapeutics (HALO), CrossFirst Bankshares (CFB) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Two Harbors Investment Corp (TWO)

58.3% sales growth and 11.19% return on equity

Two Harbors Investment Corp. operates as a real estate investment trust (REIT) that focuses on investing in, financing, and managing residential mortgage-backed securities (RMBS), non-agency securities, mortgage servicing rights, and other financial assets in the United States. Its target assets include agency RMBS collateralized by fixed rate mortgage loans, adjustable rate mortgage loans, and hybrid adjustable-rate mortgage (ARMs); and other assets, such as financial and mortgage-related assets, including non-agency securities and non-hedging transactions. The company qualifies as a REIT for federal income tax purposes. As a REIT, the company must distribute at least 90% of annual taxable income to its stockholders. Two Harbors Investment Corp. was incorporated in 2009 and is headquartered in Minnetonka, Minnesota.

Earnings per Share

Two Harbors Investment Corp’s trailing 12 months EPS is $2.48.

PE Ratio

Two Harbors Investment Corp’s trailing 12-month price-earnings ratio is 5.75. The purchaser of the shares is required to invest $5.75 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was 11.19%.

Sales Growth

Two Harbors Investment Corp’s sales growth for the next quarter is 58.3%.

Yearly Top and Bottom Value

Two Harbors Investment Corp’s stock is valued at $14.27 at 19:22 EST, way below its 52-week high of $26.20 and way above its 52-week low of $12.12.

Volume

Today’s last reported volume for Two Harbors Investment Corp is 1078340 which is 9.31% above its average volume of 986420.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on Sep 29, 2022, the estimated forward annual dividend rate is 2.72 and the estimated forward annual dividend yield is 19.06%.

2. Halozyme Therapeutics (HALO)

57.8% sales growth and 177.35% return on equity

Halozyme Therapeutics, Inc. is a platform biopharmaceutical company that operates in the United States, Switzerland, Ireland, Belgium, Japan, as well as internationally. Products of the company are built on ENHANZE, which is a patent-pending recombinant human Hyaluronidase enzyme. This technology allows for subcutaneous delivery and administration of injectable biologics such as monoclonal antibody and therapeutic molecules. Hylenex is the company’s flagship product. It uses rHuPH20 as a subcutaneous fluid delivery technology to achieve hydration. This helps to increase dispersion of radiopaque drugs and improve radiopaque agent resorption. Perjeta, RITUXAN HYCELA, and MabThera SC are also developed by the company. RITUXAN SC is for CLL patients; RITUXAN SC can be used for non-Hodgkin Lymphoma. HYQVIA treats immunodeficiency disorder. It is also developing Tecentriq, a non-small-cell lung cancer treatment; OCREVUS to treat multiple sclerosis; DARZALEX to treat patients with amyloidosis and smoldering meeloma; nivolumab to treat solid tumors; ARGX113, a human neonatal Fc receiver; ARGX117 for autoimmune disorders; and BMS-986179 an anti-CD73 antibody. F. Hoffmann-La Roche, Inc., Hoffmann-La Roche, Inc., Baxalta US Inc., Baxalta GmbH, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, Horizon Therapeutics plc, Centre for the AIDS Programme of Research, South Africa, and ViiV Healthcare Limited for small and larger molecule targets for the prevention and treatment and to treat and for HIV. Halozyme Therapeutics, Inc., was established in 1998. It is located in San Diego, California.

Earnings per Share

Halozyme Therapeutics’ trailing 12 month EPS is $2.47.

PE Ratio

Halozyme Therapeutics’ trailing 12-month price-to-earnings ratio is 20.13. The purchaser of the shares is investing $20.13 per dollar in annual earnings.

For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability and shareholder equity for a business, was 177.35%.

Sales Growth

Halozyme Therapeutics’s sales growth is 100.3% for the current quarter and 57.8% for the next.

3. CrossFirst Bankshares (CFB)

25.5% sales growth and 11.43% return on equity

CrossFirst Bankshares, Inc. operates as the bank holding company for CrossFirst Bank that provides various banking and financial services to businesses, business owners, professionals, and its personal networks. The company offers commercial real estate, construction and development, 1-4 family real estate, commercial, energy, and consumer loans. It also provides a range of deposit products consisting of noninterest-bearing demand and interest-bearing deposits, which include transaction accounts, savings accounts, money market accounts, and certificates of deposit; and personal and business checking and savings accounts, as well as negotiable order of withdrawal accounts; and brokered and reciprocal deposits. In addition, the company offers international banking services; treasury management services; automated teller machine access; and mobile banking services. Further, it holds investments in marketable securities. The company operates eight full-service banking centers located in Leawood and Wichita, Kansas; Kansas City, Missouri; Oklahoma City and Tulsa, Oklahoma; and Dallas and Frisco, Texas. CrossFirst Bankshares, Inc. was founded in 2007 and is headquartered in Leawood, Kansas.

Earnings Per Share

As for profitability, CrossFirst Bankshares has a trailing twelve months EPS of $1.48.

PE Ratio

CrossFirst Bankshares has a trailing twelve months price to earnings ratio of 9.08. Meaning,
the purchaser of the share is investing $9.08 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.43%.

Moving Average

CrossFirst Bankshares’s value is above its 50-day moving average of $13.39 and below its 200-day moving average of $14.03.

Revenue Growth

Year-on-year quarterly revenue growth declined by 1.1%, now sitting on 200.64M for the twelve trailing months.

Volume

Today’s last reported volume for CrossFirst Bankshares is 70805 which is 25.68% below its average volume of 95276.

4. Gaming and Leisure Properties (GLPI)

8.7% sales growth and 18.27% return on equity

GLPI is engaged in the business of acquiring, financing, and owning real estate property to be leased to gaming operators in triple-net lease arrangements, pursuant to which the tenant is responsible for all facility maintenance, insurance required in connection with the leased properties and the business conducted on the leased properties, taxes levied on or with respect to the leased properties and all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties.

Earnings Per Share

As for profitability, Gaming and Leisure Properties has a trailing twelve months EPS of $2.44.

PE Ratio

Gaming and Leisure Properties has a trailing twelve months price to earnings ratio of 20.62. Meaning,
the purchaser of the share is investing $20.62 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.27%.

Moving Average

Gaming and Leisure Properties’s worth is above its 50-day moving average of $47.64 and above its 200-day moving average of $46.92.

Yearly Top and Bottom Value

Gaming and Leisure Properties’s stock is valued at $50.31 at 19:23 EST, under its 52-week high of $52.87 and way higher than its 52-week low of $41.81.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Gaming and Leisure Properties’s EBITDA is 15.15.

Volume

Today’s last reported volume for Gaming and Leisure Properties is 558895 which is 69.89% below its average volume of 1856220.

5. RadNet (RDNT)

8.5% sales growth and 7.51% return on equity

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

Earnings Per Share

As for profitability, RadNet has a trailing twelve months EPS of $0.44.

PE Ratio

RadNet has a trailing twelve months price to earnings ratio of 37.7. Meaning,
the purchaser of the share is investing $37.7 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.51%.

Moving Average

RadNet’s value is way below its 50-day moving average of $19.17 and way under its 200-day moving average of $20.44.

6. Synopsys (SNPS)

5.5% sales growth and 19.02% return on equity

Synopsys, Inc. provides electronic design automation software products used to design and test integrated circuits. The company offers Fusion Design Platform that provides digital design implementation solutions; Verification Continuum Platform that provides virtual prototyping, static and formal verification, simulation, emulation, field programmable gate array (FPGA)-based prototyping, and debug solutions; and FPGA design products that are programmed to perform specific functions. It also provides intellectual property (IP) solutions for USB, PCI Express, DDR, Ethernet, SATA, MIPI, HDMI, and Bluetooth low energy applications; analog IP, including data converters and audio codecs; and system-on-chip (SoC) infrastructure IP, datapath and building block IP, and verification IP products, as well as mathematical and floating-point components, and Arm AMBA interconnect fabric and peripherals. In addition, the company offers logic libraries and embedded memories; configurable processor cores and application-specific instruction-set processor tools for embedded applications; IP subsystems for audio, sensor, and data fusion functionality; and security IP solutions. Further, it provides Platform Architect solutions for SoC architecture analysis and optimization; virtual prototyping solutions; and HAPS FPGA-based prototyping systems, as well as a series of tools used in the design of optical systems and photonic devices. Additionally, the company offers security testing, managed services, programs and professional services, and training that enable its customers to detect and remediate security vulnerabilities, and defects in the software development lifecycle, as well as manufacturing solutions. It serves electronics, financial services, automotive, medicine, energy, and industrial areas. The company was incorporated in 1986 and is headquartered in Mountain View, California.

Earnings Per Share

As for profitability, Synopsys has a trailing twelve months EPS of $4.62.

PE Ratio

Synopsys has a trailing twelve months price to earnings ratio of 70.68. Meaning,
the purchaser of the share is investing $70.68 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.02%.

Sales Growth

Synopsys’s sales growth is 11.2% for the current quarter and 5.5% for the next.

Yearly Top and Bottom Value

Synopsys’s stock is valued at $326.89 at 19:23 EST, way under its 52-week high of $391.17 and way higher than its 52-week low of $255.02.

Revenue Growth

Year-on-year quarterly revenue growth grew by 18%, now sitting on 4.95B for the twelve trailing months.